



National Report on
Patient Outcomes in
Palliative Care
in Australia

January – June 2014

Report 17

September 2014



About the Palliative Care Outcomes Collaboration

The Palliative Care Outcomes Collaboration (PCOC) is a national program that utilises standardised clinical assessment tools to measure and benchmark patient outcomes in palliative care. Participation in PCOC is voluntary and can assist palliative care service providers to improve practice and meet the Palliative Care Australia (PCA) Standards for Providing Quality Palliative Care for all Australians. This is achieved via the PCOC dataset; a multi-purpose framework designed to:

- provide clinicians with an approach to systematically assess individual patient experiences,
- define a common clinical language to streamline communication between palliative care providers and
- facilitate the routine collection of national palliative care data to drive quality improvement through reporting and benchmarking.

The PCOC dataset includes the clinical assessment tools: Palliative Care Phase, Palliative Care Problem Severity Score (PCPSS), Symptom Assessment Scale (SAS), Australia-modified Karnofsky Performance Status (AKPS) scale and Resource Utilisation Groups – Activities of Daily Living (RUG-ADL).

PCOC has divided Australia into four zones for the purpose of engaging with palliative care service providers. Each zone is represented by a chief investigator from one of the collaborative centres. The four PCOC zones and their respective chief investigators are:



Each zone is also represented by one or more quality improvement facilitators, whose role includes supporting services to participate in PCOC and facilitating ongoing service development and quality improvement. The national team, located within the Australian Health Services Research Institute at the University of Wollongong, coordinates the patient outcomes reporting, education program, and quality activities across the four zones.

If you would like more information or have any queries about this report please contact your local quality improvement facilitator or contact the national office at pcoc@uow.edu.au or phone (02) 4221 4411.



Table of Contents

Introduct	ion	1
Section 1		2
1.1	Australian Outcomes at a glance	2
1.2	National benchmark profiles	3
Section 2	Outcome measures in detail	16
2.1	Outcome measure 1 – Time from date ready for care to episode start	
2.2	Outcome measure 2 – Time in unstable phase	
2.3	Outcome measure 3 – Change in pain	20
2.4	Outcome measure 4 – Change in symptoms relative to the baseline national average (X-CAS)	
Section 3	Descriptive analysis	26
3.1	Profile of palliative care patients	27
3.2	Profile of palliative care patients	32
3.3	Profile of palliative care phases	38
Appendix	A Summary of data included in this reporta summary	50
A1 Dat	a summary	50
A2 Dat	a item completion	52
	B Data scoping method	
Appendix	C X-CAS technical notes	55
	D Palliative Care Phase definitions	
	edgements	



List of Tables

Table 1 Summary of outcome measures 1 to 3 by setting	2
Table 2 Summary of outcome measure 4: Average improvement on the 2008 baseline national average (X-CAS)	2
Table 3 Time from date ready for care to episode start by setting	16
Table 4 Time in unstable phase by setting	18
Table 5 Trends in benchmark 3.1: PCPSS Patients with absent/mild pain at phase start, remaining absent/mild at phase end by setting	20
Table 6 Trends in benchmark 3.2: PCPSS Patients with moderate/severe pain at phase start, with absent/mild pain at phase end by setting	20
Table 7 Trends in benchmark 3.3: SAS Patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end by setting	21
Table 8 Trends in benchmark 3.4: SAS Patients experience moderate/severe distress from pain at phase start, with absent/mild pain at phase end by setting	21
Table 9 Indigenous status	27
Table 10 Place of death	27
Table 11 Preferred language	28
Table 12 Country of birth	29
Table 13 Primary diagnosis - malignant	30
Table 14 Primary diagnosis - non-malignant	31
Table 15 Age group by sex	32
Table 16 Referral source by setting	33
Table 17 Referral to first contact by episode setting	34
Table 18 Length of episode (in days) summary by setting	35
Table 19 Length of episode (in days) by setting	35
Table 20 How episodes start – inpatient setting	36
Table 21 How episodes end – inpatient setting	36
Table 22 How episodes start – community setting	37
Table 23 How episodes end – community setting	37
Table 24 Number of phases by phase type and setting	38
Table 25 Average phase length (in days) by phase type and setting	38
Table 26 How stable phases end – by setting	39
Table 27 How unstable phases end – by setting	40
Table 28 How deteriorating phases end – by setting	41
Table 29 How terminal phases end – by setting	42
Table 30 Profile of PCPSS at beginning of phase by phase type – inpatient setting (percentages)	43
Table 31 Profile of PCPSS at beginning of phase by phase type –community setting (percentages)	44



Table 32 Profile of SAS scores at beginning of phase by phase type – inpatient setting (percentages)	45
Table 33 Profile of SAS scores at beginning of phase by phase type –community setting (percentages)	46
Table 34 Australia-modified Karnofsky Performance Status (AKPS) at phase start by setting	47
Table 35 Number and percentage of patients, episodes and phases by setting	50
Table 36 Number of completed episodes and phases by month and setting	51
Table 37 Item completion (per cent complete) - patient level	
Table 38 Item completion by setting (per cent complete) - episode level	
Table 39 Item completion by setting (per cent complete) - phase level	



List of Figures

Figure 1	Percentage of patients with episode started on the day of, or the day after date ready for care – inpatient setting setting	4
Figure 2	Percentage of patients with episodes started on the day of, or the day after date ready for care – community setting	5
Figure 3	Percentage of patients in the unstable phase for 3 days or less – inpatient setting	6
Figure 4	Percentage of patients in the unstable phase for 3 days or less – community setting	7
Figure 5	PCPSS: Percentage of patients with absent/mild pain at phase start, remaining absent/mild at phase end – inpatient setting	8
Figure 6	PCPSS: Percentage of patients with absent/mild pain at phase start, remaining absent/mild at phase end – community setting	9
Figure 7	PCPSS: Percentage of patients with moderate/severe pain at phase start, with absent/mild pain at phase end – inpatient setting	10
Figure 8	PCPSS: Percentage of patients with moderate/severe pain at phase start, with absent/mild pain at phase end – community setting	11
Figure 9	SAS: Percentage of patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end – inpatient setting	12
Figure 10	SAS: Percentage of patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end – community setting	13
Figure 11	SAS: Percentage of patients with moderate/severe distress from pain at phase start, with absent/mild distress from pain at phase end – inpatient setting	14
Figure 12	SAS: Percentage of patients with moderate/severe distress from pain at phase start, with absent/mild distress from pain at phase end – community setting	15
Figure 13	Trends in outcome measure 1	17
_	Trends in outcome measure 2	
Figure 15	Trends in outcome measure 3	22
Figure 16	Trends in outcome measure 4 – Palliative Care Problem Severity Score (PCPSS)	24
	Trends in outcome measure 4 – Symptom Assessment Scale (SAS)	
Figure 18	Stable phase progression – inpatient setting	39
Figure 19	Stable phase progression – community setting	39
Figure 20	Unstable phase progression – inpatient setting	40
_	Unstable phase progression – community setting	
Figure 22	Deteriorating phase progression – inpatient setting	41
Figure 23	Deteriorating phase progression – community setting	41
Figure 24	Terminal phase progression – inpatient setting	42
Figure 25	Terminal phase progression – community setting	42
Figure 26	Total RUG-ADL at beginning of phase by phase type – inpatient setting	48
Figure 27	Total RUG-ADL at beginning of phase by phase type – community setting	49
Figure 28	Diagram of the PCOC data scoping method	54



Introduction

The Palliative Care Outcomes Collaboration (PCOC) assists services to improve the quality of the palliative care they provide through the analysis and benchmarking of patient outcomes. In this, the seventeenth PCOC report, data submitted for the January to June 2014 period are summarised and patient outcomes benchmarked to enable participating services to assess their performance and identify areas in which they may improve.

Patient outcomes are reported for a total of 16,833 patients, with 21,518 episodes of care and 49,643 palliative care phases. The information included in this report is determined by a data scoping methods. See Appendix A for more information on the data included in this report.

The national figures are based on information submitted by 93 services, of which:

- 53 are inpatient services. Inpatient services include patients who have been seen in designated palliative care beds as well as non-designated bed consultations.
- 27 are community services. These services include primarily patients seen in the community as well as some patients with ambulatory/clinic episodes.
- 13 are services with both inpatient and community settings.

A full list of the services included in the national figures can be found at www.pcoc.org.au.

Interpretation hint:

Some tables throughout this report may be incomplete. This is because some items may not be applicable or it may be due to data quality issues.

Please use the following key when interpreting the tables:

- na The item is not applicable.
- u The item was unavailable.
- s The item was suppressed due to insufficient data as there was less than 10 observations.



Section 1 Benchmark summary

1.1 Australian Outcomes at a glance

Table 1 Summary of outcome measures 1 to 3 by setting

			Inpatient		Community	
Outcome measure	Description	Benchmark	Score (%)	Benchmark Met?	Score (%)	Benchmark Met?
1. Time from ready for care to episode start	Benchmark 1: Patients episode commences on the day of, or the day after date ready for care	90%	95.7	Yes	84.3	No
2. Time in unstable phase	Benchmark 2: Patients in the unstable phase for 3 days or less	90%	82.8	No	70.7	No
3. Change in pain	Benchmark 3.1: PCPSS Patients with absent/mild pain at phase start, remaining absent/mild at phase end	90%	90.1	Yes	84.9	No
	Benchmark 3.2: PCPSS Patients with moderate/severe pain at phase start, with absent/mild pain at phase end	60%	56.1	No	52.5	No
	Benchmark 3.3: SAS Patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end	90%	88.7	No	82.4	No
	Benchmark 3.4: SAS Patients with moderate/severe distress from pain at phase start, with absent/mild at phase end	60%	52.1	No	48.4	No

Table 2 Summary of outcome measure 4: Average improvement on the 2008 baseline national average (X-CAS)

Clinical Tool	Description	Average improvement on baseline	Benchmark met?
PCPSS	Benchmark 4.1: Pain	0.20	Yes
	Benchmark 4.2: Other symptoms	0.41	Yes
	Benchmark 4.3: Family/carer	0.25	Yes
	Benchmark 4.4: Psychological/spiritual	0.22	Yes
SAS	Benchmark 4.5: Pain	0.39	Yes
	Benchmark 4.6: Nausea	0.23	Yes
	Benchmark 4.7: Breathing problems	0.44	Yes
	Benchmark 4.8: Bowel problems	0.42	Yes

The benchmark for outcome measure 4 is zero.

For more information on the outcome measures and benchmarks, see

Section 2 and Appendix C.



1.2 National benchmark profiles

In this section, the national profiles for selected benchmarks are split by setting (inpatient or community) and presented graphically.

The selected benchmarks included are:

•	Benchmark 1	Patients episode commences on the day of or the day after date ready for care
•	Benchmark 2	Patients in the unstable phase for 3 days or less
•	Benchmark 3.1	PCPSS: Patients with absent/mild pain at phase start, remaining absent/mild at phase end
•	Benchmark 3.2	PCPSS: Patients with moderate/severe pain at phase start, with absent/mild pain at phase end
•	Benchmark 3.3	SAS: Patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end
•	Benchmark 3.4	SAS: Patients with moderate/severe distress from pain at phase start, with absent/mild distress from pain at phase end

Interpretation hint:

The national profile graphs on the following pages, allows services to see how they are performing in comparison to other palliative care services participating in PCOC. In each graph, the shaded region describes the national profile for that outcome measure.



Outcome measure 1 – Time from date ready for care to episode start Benchmark 1

Figure 1 Percentage of patients with episode started on the day of, or the day after date ready for care – inpatient setting







Figure 2 Percentage of patients with episodes started on the day of, or the day after date ready for care – community setting





Outcome measure 2 – Time in unstable phase Benchmark 2

Figure 3 Percentage of patients in the unstable phase for 3 days or less – inpatient setting







Figure 4 Percentage of patients in the unstable phase for 3 days or less – community setting





Outcome measure 3 – Change in pain Benchmark 3.1

Figure 5 PCPSS: Percentage of patients with absent/mild pain at phase start, remaining absent/mild at phase end – inpatient setting







Figure 6 PCPSS: Percentage of patients with absent/mild pain at phase start, remaining absent/mild at phase end – community setting





Benchmark 3.2

Figure 7 PCPSS: Percentage of patients with moderate/severe pain at phase start, with absent/mild pain at phase end – inpatient setting







Figure 8 PCPSS: Percentage of patients with moderate/severe pain at phase start, with absent/mild pain at phase end – community setting





Benchmark 3.3

Figure 9 SAS: Percentage of patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end – inpatient setting







Figure 10 SAS: Percentage of patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end – community setting





Benchmark 3.4

Figure 11 SAS: Percentage of patients with moderate/severe distress from pain at phase start, with absent/mild distress from pain at phase end – inpatient setting







Figure 12 SAS: Percentage of patients with moderate/severe distress from pain at phase start, with absent/mild distress from pain at phase end – community setting





Section 2 Outcome measures in detail

2.1 Outcome measure 1 – Time from date ready for care to episode start

Time from date ready for care to episode start measures responsiveness of palliative care services to patient needs. This benchmark was set following feedback and subsequent consultation with PCOC participants. Service providers acknowledge that, whilst there is wide variation in the delivery of palliative care across the country, access to palliative care should be measured based on patient need rather than service availability. As a result, services operating five days a week (Monday to Friday) are not distinguished from services operating seven days a week (all services are being benchmarked together).

Benchmark 1:

This benchmark relates to the time taken for an episode to commence following the date the patient is available and ready to receive palliative care. To meet the benchmark for this measure, at least 90% of patients must have their episode commence on the day of, or the day following date ready for care.

Table 3 Time from date ready for care to episode start by setting

Time (in days)	Inpatie	nt	Community		
Time (in days)	N	%	N	%	
Same day	9,348	88.9	7,167	79.1	
Following day	712	6.8	474	5.2	
2-7 days	397	3.8	1,008	11.1	
8-14 days	42	0.4	210	2.3	
Greater than 14 days	18	0.2	203	2.2	
Average	1.2	na	2.4	na	
Median	1	na	1	na	

Note: Only episodes that started in this reporting period have been included in the table. Episodes where date ready for care was not recorded are excluded from the table. In addition, all records where time from date ready for care to episode start was greater than 90 days were considered to be atypical and were assumed to equal 90 days for the purpose of calculating the average and median time.


Interpretation hint:

Outcome measure 1 only includes episodes that have commenced in the reporting period. As a result, the number of episodes included in the calculation of this benchmark may not match the number of episodes in Appendix A. For more information on data scoping methods, see Appendix B.




Figure 13 Trends in outcome measure 1

Inpatient setting



Community setting





2.2 Outcome measure 2 – Time in unstable phase

The unstable phase type, by nature of its definition, alerts clinical staff to the need for urgent changes to the patient's plan of care or that emergency intervention is required. Those patients assessed to be in the unstable phase require intense review for a short period of time.

An unstable phase is triggered if:

- a patient experiences a new, unanticipated problem, and/or
- a patient experiences a rapid increase in the severity of an existing problem, and/or
- a patient's family/carers experience a sudden change in circumstances that adversely impacts the patient's care.

The patient moves out of the unstable phase in one of two ways:

- A new plan of care has been put in place, has been reviewed and does not require any additional changes. This does not necessarily mean that the symptom/crisis has been fully resolved. However, the clinical team will have a clear diagnosis and a plan for the patient's care. In this situation, the patient will move to either the stable or deteriorating phase.
- The patient is likely to die within a matter of days. In this situation, the patient will be moved into the terminal phase.

Benchmark 2: This benchmark relates to time that a patient spends in the unstable phase. To meet this benchmark, at least 90% of unstable phases must last for 3 days or less.


Table 4 Time in unstable phase by setting

Laurih of watable whose	Inpa	tient	Community		
Length of unstable phase	N	%	N	%	
Same day	241	3.8	555	20.6	
1 day	2,684	42.8	885	32.9	
2 days	1,515	24.2	285	10.6	
3 days	752	12.0	175	6.5	
4-5 days	621	9.9	193	7.2	
6-7 days	246	3.9	127	4.7	
8-14 days	177	2.8	170	6.3	
Greater than 14 days	37	0.6	299	11.1	
Total	6,273	100.0	2,689	100.0	




Figure 14 Trends in outcome measure 2

Inpatient setting



Community setting





2.3 Outcome measure 3 – Change in pain

Pain management is acknowledged as a core business of palliative care services. The Palliative Care Problem Severity Score (PCPSS) and Symptom Assessment Scale (SAS) provide two different perspectives of pain. The PCPSS is clinician rated and measures the severity of pain as a clinical problem while the SAS is patient rated and measures distress caused by pain. There are two benchmarks related to each tool: one relating to the management of pain for patients with absent or mild pain (Table 5 and Table 7), and the other relating to the management of pain for patients with moderate or severe pain (Table 6 and Table 8). For the analysis in this report SAS scores have been grouped as 0 absent, 1-3 mild, 4-7 moderate and 8-10 severe. Phase records must have valid start and end scores for the PCPSS and/or SAS clinical assessment tools to be included in the benchmarks.

Benchmark 3.1: This benchmark relates to patients who have absent or mild pain at the start of their phase of palliative care, as rated via the PCPSS clinical tool.

To meet this benchmark, 90% of these phases must end with the patient still experiencing only absent or mild pain.

Table 5 Trends in benchmark 3.1: PCPSS Patients with absent/mild pain at phase start, remaining absent/mild at phase end by setting

Setting	PCPSS	Jul-Dec 2012	Jan-Jun 2013	Jul-Dec 2013	Jan-Jun 2014
Inpatient	Start absent/mild (N)*	10,155	11,577	15,025	14,142
працепц	End absent/mild (%)	86.0	88.5	88.5	90.1
Community	Start absent/mild (N)*	10,424	10,700	13,454	13,873
Community	End absent/mild (%)	83.4	82.6	83.2	84.9

^{*}Total number of phases included in this benchmark.

Benchmark 3.2: This benchmark relates to patients who have moderate or severe pain at the start of their phase of palliative care, as rated via the PCPSS clinical tool. To meet this benchmark, 60% of these phases must end with the patient's pain reduced to being absent or mild.

Table 6 Trends in benchmark 3.2: PCPSS Patients with moderate/severe pain at phase start, with absent/mild pain at phase end by setting

Setting	PCPSS	Jul-Dec 2012	Jan-Jun 2013	Jul-Dec 2013	Jan-Jun 2014
Inpatient	Start moderate/severe (N)*	4,653	4,876	5,822	5,181
inpatient	End absent/mild (%)	52.8	56.2	53.8	56.1
Community	Start moderate/severe (N)*	3,006	3,144	3,896	3,612
Community	End absent/mild (%)	51.6	51.7	51.8	52.5

^{*}Total number of phases included in this benchmark.



Benchmark 3.3: This benchmark relates to patients who have absent or mild pain at the start of their phase of palliative care, as rated via the SAS clinical tool. To meet this benchmark, 90% of these phases must end with the patient still experiencing only absent or mild pain.

Table 7 Trends in benchmark 3.3: SAS Patients with absent/mild distress from pain at phase start, remaining absent/mild at phase end by setting

Setting	SAS	Jul-Dec 2012	Jan-Jun 2013	Jul-Dec 2013	Jan-Jun 2014
Inpatient	Start absent/mild (N)*	11,302	11,646	13,788	12,669
IIIpatieIIt	End absent/mild (%)	85.3	87.8	87.0	88.7
Community	Start absent/mild (N)*	10,052	10,171	12,752	13,209
Community	End absent/mild (%)	81.8	81.2	81.2	82.4

^{*}Total number of phases included in this benchmark.

Benchmark 3.4: This benchmark relates to patients who have moderate or severe pain at the start of their phase of palliative care, as rated via the SAS clinical tool. To meet this benchmark, 60% of these phases must end with the patient's pain reduced to being absent or mild.

Table 8 Trends in benchmark 3.4: SAS Patients experience moderate/severe distress from pain at phase start, with absent/mild pain at phase end by setting

	Setting	SAS	Jul-Dec 2012	Jan-Jun 2013	Jul-Dec 2013	Jan-Jun 2014
	Inpatient	Start moderate/severe (N)*	5,858	5,890	6,956	6,027
		End absent/mild (%)	49.0	51.4	50.4	52.1
	Community	Start moderate/severe (N)*	3,557	3,676	4,756	4,287
		End absent/mild (%)	46.8	47.5	48.7	48.4

^{*}Total number of phases included in this benchmark.


Interpretation hint:

For this report, the number (N) shown in Table 5 to Table 8 has changed. In past reports, only the number of phases that met the benchmark was shown. This has been changed to report on the total number of phases included in the benchmark. As a result of this change, past reports will display a different number but the percentage remains the same.




Figure 15 Trends in outcome measure 3


Benchmark 3.1: PCPSS - Absent/mild pain at both start and end of phase



Benchmark 3.2: PCPSS - Moderate/severe pain at start with absent/mild pain at end



Benchmark 3.3: SAS - Absent/mild pain at both start and end of phase



Benchmark 3.4: SAS - Moderate/severe pain at start with absent/mild pain at end





2.4 Outcome measure 4 – Change in symptoms relative to the baseline national average (X-CAS)

Outcome measure 4 includes a suite of case-mix adjusted scores used to compare the change in symptoms for similar patients i.e. patients in the same phase who started with the same level of symptom. Eight symptoms are included in this report:

PCPSS	SAS
4.1 Pain	4.5 Pain
4.2 Other symptoms	4.6 Nausea
4.3 Family/carer	4.7 Breathing problems
4.4 Psychological/spiritual	4.8 Bowel problems

The suite of benchmarks included in outcome measure 4 are generally referred to as <u>X-CAS</u> – *CAS* standing for *Case-mix Adjusted Score*, and the *X* to represent that multiple symptoms are included.

Interpretation hint:

The X-CAS measures are calculated relative to a baseline reference period (currently July to December 2008). As a result:

If X-CAS is greater than 0 then on average, the patients' change in symptom was better than similar patients in the baseline reference period.

If X-CAS is <u>equal to 0</u> then on average, the patients' change in symptom was <u>about the same as similar patients</u> in the baseline reference period.


If X-CAS is <u>less than 0</u> then on average, the patients' change in symptom was <u>worse than similar patients</u> in the baseline reference period.


As X-CAS looks at change in symptom, they are only able to be calculated on phases which ended in phase change or discharge (as the phase end scores are required to determine the change). Bereavement phases are excluded from the analysis.


A more technical explanation of X-CAS is included in Appendix C.




Figure 16 Trends in outcome measure 4 – Palliative Care Problem Severity Score (PCPSS)












Note: Only services with 10 or more valid assessments are included in the above graphs.




Figure 17 Trends in outcome measure 4 – Symptom Assessment Scale (SAS)









Note: Only services with 10 or more valid assessments are included in the above graphs.



Section 3 Descriptive analysis

Information is collected at three levels – patient, episode and phase.

Patient level includes data items relating to patient demographic. The information collected on each patient includes Indigenous status, sex, preferred language and country of birth.

Episode level includes data items which focus on characterising the setting of palliative care service provision. It also provides information relating to the facility or organisation that has referred the patient as well as how a palliative care episode starts and ends.

Phase level data items describe a palliative care patient's stage of illness, functional impairment and levels of pain and symptom distress, using five clinical assessment tools.

This section provides an overview of the data submitted for the current reporting period.



3.1 Profile of palliative care patients

PCOC defines a patient as a person for whom a palliative care service accepts responsibility for assessment and/or treatment as evidenced by the existence of a medical record. Family/carers are included in this definition if interventions relating to them are recorded in the patient medical record. For the purpose of palliative care this includes the bereaved family of the deceased patient (particularly for the bereavement phase).

Table 9 shows the Indigenous status for all the patients nationally.

Table 9 Indigenous status

Indigenous status	N	%
Aboriginal but not Torres Strait Islander origin	141	0.8
Torres Strait Islander but not Aboriginal origin	14	0.1
Both Aboriginal and Torres Strait Islander origin	13	0.1
Neither Aboriginal nor Torres Strait Islander origin	16,333	97.0
Not stated/inadequately described	332	2.0
Total	16,833	100.0

Table 10 shows the breakdown of deaths for all patients nationally. All inpatient deaths are reported in the hospital category while the community deaths can be found in the private residence and residential aged care facility categories.

Table 10 Place of death

Place of death	N	%
Private residence	1,714	20.7
Residential aged care facility	548	6.6
Hospital	5,829	70.3
Not stated/inadequately described	205	2.5
Total	8,296	100.0



The following two tables show the preferred language and the country of birth respectively for all patients nationally. To allow for comparison with the broader Australian community the list of languages in Table 11 is in descending order of the most frequently spoken languages according to the 2006 Census (e.g. Greek was the third most frequently spoken language in the 2006 Census). The same approach has been taken with Table 12 (e.g. Italy was the fifth highest country of birth in the 2006 Census). All other languages and countries have been grouped together to form the categories 'All other languages' and 'All other countries' respectively.

Table 11 Preferred language

Preferred language	N	%
English	15,092	89.7
Italian	373	2.2
Greek	261	1.6
Cantonese/Mandarin	141	0.8
Arabic	116	0.7
Vietnamese	57	0.3
Spanish/Portuguese	44	0.3
Filipino	23	0.1
German	34	0.2
Hindi	25	0.1
Macedonian/Croatian	121	0.7
Korean	16	0.1
Turkish	33	0.2
Polish	21	0.1
Maltese	19	0.1
All other languages	447	2.7
Not stated/inadequately described	10	0.1
Total	16,833	100.0



Table 12 Country of birth

Country of birth	N	%
Australia	10,640	63.2
England	1,190	7.1
New Zealand	274	1.6
China	156	0.9
Italy	700	4.2
Vietnam	107	0.6
India	127	0.8
Scotland	228	1.4
Philippines	66	0.4
Greece	364	2.2
Germany	235	1.4
South Africa	94	0.6
Malaysia	46	0.3
Netherlands	170	1.0
Lebanon	88	0.5
All other countries	2,139	12.7
Not stated/inadequately described	209	1.2
Total	16,833	100.0



Table 13 and Table 14 present a breakdown of malignant and non-malignant diagnosis for all patients at the national level. The primary diagnosis is the principal life limiting illness responsible for the patient requiring palliative care.

The primary diagnosis was not stated for 60 (0.4%) patients nationally.

Table 13 Primary diagnosis - malignant

Primary diagnosis	N	% malignant diagnosis	% all diagnosis
Bone and soft tissue	195	1.5	1.2
Breast	1,041	7.9	6.2
CNS	304	2.3	1.8
Colorectal	1,559	11.8	9.3
Other GIT	1,263	9.5	7.5
Haematological	829	6.3	4.9
Head and neck	689	5.2	4.1
Lung	2,927	22.1	17.4
Pancreas	790	6.0	4.7
Prostate	919	6.9	5.5
Other urological	562	4.2	3.3
Gynaecological	666	5.0	4.0
Skin	509	3.8	3.0
Unknown primary	375	2.8	2.2
Other primary malignancy	514	3.9	3.1
Malignant – not further defined	93	0.7	0.6
All malignant	13,235	100.0	78.6



Table 14 Primary diagnosis - non-malignant

Primary diagnosis	N	% non-malignant diagnosis	% all diagnosis
Cardiovascular disease	652	18.4	3.9
HIV/AIDS	11	0.3	0.1
End stage kidney disease	342	9.7	2.0
Stroke	171	4.8	1.0
Motor neurone disease	140	4.0	0.8
Alzheimer's dementia	97	2.7	0.6
Other dementia	183	5.2	1.1
Other neurological disease	367	10.4	2.2
Respiratory failure	623	17.6	3.7
End stage liver disease	136	3.8	0.8
Diabetes and its complications	17	0.5	0.1
Sepsis	93	2.6	0.6
Multiple organ failure	77	2.2	0.5
Other non-malignancy	577	16.3	3.4
Non-malignant – not further defined	52	1.5	0.3
All non-malignant	3,538	100.0	21.0



3.2 Profile of palliative care episodes

An episode of care is a period of contact between a patient and a palliative care service that is provided by one palliative care service and occurs in one setting – for the purposes of this report, either as an inpatient or community patient.

An episode of palliative care starts on the date when the comprehensive palliative care assessment is undertaken and documented using the five clinical assessment tools.

An episode of palliative care ends when:

- the patient is formally separated from the current setting of care (e.g. from community to inpatient) or
- the patient dies or
- the principal clinical intent of the care changes and the patient is no longer receiving palliative care.

Table 15 below presents the number and percentage of episodes by age group and sex for the patients seen at the national level. Age has been calculated as at the beginning of each episode.

Table 15 Age group by sex

A sia sina sina	Male		Female	
Age group	N	%	N	%
< 15	36	0.3	23	0.2
15 - 24	36	0.3	39	0.4
25 - 34	77	0.7	94	0.9
35 - 44	227	2.0	315	3.2
45 - 54	704	6.1	832	8.3
55 - 64	1,752	15.2	1,545	15.5
65 - 74	3,046	26.4	2,311	23.1
75 - 84	3,508	30.4	2,654	26.6
85+	2,135	18.5	2,182	21.8
Not stated/inadequately described	0	0.0	0	0.0
Total	11,521	100.0	9,995	100.0

Note: Records where sex was not stated or inadequately described are excluded from the table.



Referral source refers to the facility or organisation from which the patient was referred for each episode of care. Table 16 presents referral source by episode type. Review of referral source can identify opportunities to connect with referral sources that are currently lower than the national referral profile (e.g. a community service with few GP referrals may want to re-address referral or triage practices and look to working more collaboratively).

Table 16 Referral source by setting

Referral source	Inpatient		Community	
Referral source	N	%	N	%
Public hospital	5,859	51.9	5,075	49.6
Private hospital	1,352	12.0	1,106	10.8
Outpatient clinic	37	0.3	32	0.3
General medical practitioner	353	3.1	1,504	14.7
Specialist medical practitioner	626	5.5	466	4.6
Community-based palliative care agency	2,460	21.8	181	1.8
Community-based service	51	0.5	141	1.4
Residential aged care facility	105	0.9	914	8.9
Self, carer(s), family or friends	237	2.1	391	3.8
Other	133	1.2	254	2.5
Not stated/inadequately described	73	0.6	168	1.6
Total	11,286	100.0	10,232	100.0



Table 17 provides a summary of the time between referral to first contact by setting of care. The time from referral to first contact is calculated as the time from the date of referral received to either the date of first contact (if provided) or the episode start date.

Table 17 Referral to first contact by episode setting

Time (in days)	Inpatier	nt	Community	
Time (in days)	N	%	N	%
Same day or following day	10,418	92.3	5,245	51.3
2-7 days	742	6.6	3,596	35.2
8-14 days	80	0.7	797	7.8
Greater than 14 days	45	0.4	587	5.7
Average	1.2	na	2.8	na
Median	1	na	1	na

Note: Episodes where referral date was not recorded are excluded from the table. In addition, all records where time from referral to first contact was greater than 7 days were considered to be atypical and were assumed to equal 7 days for the purpose of calculating the average and median time.



Table 18 gives a summary of the length of episode for patients nationally. Table 19 details the length of episode by setting. The length of episode is calculated as the number of days between the episode start date and the episode end date. Bereavement phases are excluded from the calculation and episodes that remain open at the end of the reporting period (and hence do not have an episode end date) are also excluded.

Table 18 Length of episode (in days) summary by setting

Length of episode	Inpatient	Community
Average length of episode	10.9	40.0
Median length of episode	6.0	28.0

Note: Records where length of episode was greater than 180 days were considered to be atypical and are excluded from the average calculations. Only episode ending during the reporting period are included.

Table 19 Length of episode (in days) by setting

Longth of opioods	Inpatient		Community	
Length of episode	N	%	N	%
Same day	657	5.9	487	5.3
1-2 days	2,248	20.1	558	6.1
3-4 days	1,609	14.4	456	5.0
5-7 days	1,794	16.1	624	6.8
8-14 days	2,337	20.9	1,062	11.6
15-21 days	1,030	9.2	805	8.8
22-30 days	630	5.6	769	8.4
31-60 days	653	5.9	1,628	17.9
61-90 days	142	1.3	877	9.6
Greater than 90 days	57	0.5	1,854	20.3
Total	11,157	100.0	9,120	100.0

Note: Only episode ending during the reporting period are included.

Table 20 How episodes start – inpatient setting

Episode start mode	N	%
Admitted from community	7,172	63.5
Admitted from another hospital	2,854	25.3
Admitted from acute care in another ward	1,049	9.3
Other*	201	1.8
Not stated/inadequately described	10	0.1
Total	11,286	100.0

^{*} includes: change from acute care to palliative care while remaining on same ward; change of sub-acute/non-acute care type.

Table 21 How episodes end – inpatient setting

Episode end mode	N	%
Discharged to community	3,781	33.9
Discharged to another hospital	825	7.4
Death	5,829	52.2
Other*	386	3.5
Not stated/inadequately described	336	3.0
Total	11,157	100.0

Note: Only episode ending during the reporting period are included.

^{*} includes: change from palliative care to acute care - different ward; change from palliative care to acute care - same ward; change in sub-acute care type; end of consultative episode – inpatient episode ongoing.



Table 22 How episodes start – community setting

Episode start mode	N	%
Admitted from inpatient palliative care	3,961	38.7
Other	6,208	60.7
Not stated/inadequately described	63	0.6
Total	10,232	100.0

Table 23 How episodes end – community setting

Episode end mode	N	%
Admitted for inpatient palliative care	2,562	28.1
Admitted for inpatient acute care	2,515	27.6
Discharged/case closure	874	9.6
Death	2,467	27.1
Other	698	7.7
Not stated/inadequately described	4	0.0
Total	9,120	100.0

Note: Only episode ending during the reporting period are included.

^{*} includes: admitted to another palliative care service, admitted to primary health care and other categories.



3.3 Profile of palliative care phases

The palliative care phase type describes the stage of the patient's illness and provides a clinical indication of the level of care a patient requires. There are five palliative care phase types; stable, unstable, deteriorating, terminal and bereaved. The palliative care phase is determined by a holistic clinical assessment which considers the needs of the patients and their family and carers. A patient may move back and forth between the stable, unstable, deteriorating and terminal phase types and these may occur in any sequence. See Appendix D for more information on the definition of palliative care phase.

Table 24 Number of phases by phase type and setting

Inpat		ient Commun		nunity
Phase type	N	%	N	%
Stable	6,664	24.8	8,497	37.3
Unstable	6,273	23.3	2,689	11.8
Deteriorating	8,105	30.1	9,585	42.1
Terminal	4,971	18.5	1,796	7.9
Bereaved	874	3.3	189	0.8
Total phases	26,887	100.0	22,756	100.0

Table 25 Average phase length (in days) by phase type and setting

Phase type	Inpatient	Community
Stable	7.1	20.7
Unstable	2.4	5.5
Deteriorating	5.6	13.5
Terminal	2.0	3.2
Bereaved	1.8	25.5

Note: Phase records where phase length was greater than 90 days were considered to be atypical and are excluded from the average calculations.



Table 26 presents information relating to the manner in which stable phases ended. A stable phase will end if a patient moves into a different phase (phase change), is discharged or dies. Figure 18 and Figure 19 summarise the movement of patients out of the stable phase for the inpatient and community settings. This movement from one phase to another is referred to as phase progression. The phase progression information is derived by PCOC.

Similar information is presented for the unstable (Table 27, Figure 20 and Figure 21), deteriorating (Table 28, Figure 22 and Figure 23) and terminal (Table 28, Figure 24 and Figure 25) phases on the following pages.

Table 26 How stable phases end - by setting

How stable whose and	Inpatient		Community	
How stable phases end	N	%	N	%
Patient moved into another phase	3,366	50.5	5,469	64.4
Discharge/case closure	3,208	48.1	2,756	32.4
Died	88	1.3	260	3.1
Not stated/inadequately described	2	0.0	12	0.1
Total	6,664	100.0	8,497	100.0

Figure 18 Stable phase progression – inpatient setting




Figure 19 Stable phase progression – community setting






Table 27 How <u>unstable</u> phases end – by setting

Henry unetable ubecome and	Inpatie	nt	Community		
How unstable phases end	N	%	N	%	
Patient moved into another phase	5,665	90.3	1,795	66.8	
Discharge/case closure	467	7.4	812	30.2	
Died	140	2.2	79	2.9	
Not stated/inadequately described	1	0.0	3	0.1	
Total	6,273	100.0	2,689	100.0	

Figure 20 Unstable phase progression – inpatient setting




Figure 21 Unstable phase progression – community setting






Table 28 How <u>deteriorating</u> phases end – by setting

Have deterioration above and	Inpatie	nt	Community		
How deteriorating phases end	N	%	N	%	
Patient moved into another phase	5,579	68.8	5,870	61.2	
Discharge/case closure	1,541	19.0	2,952	30.8	
Died	978	12.1	762	7.9	
Not stated/inadequately described	7	0.1	1	0.0	
Total	8,105	100.0	9,585	100.0	

Figure 22 Deteriorating phase progression – inpatient setting




Figure 23 Deteriorating phase progression – community setting






Table 29 How <u>terminal</u> phases end – by setting

Have tarminal phases and	Inpatie	Inpatient		nity
How terminal phases end	N	%	N	%
Patient moved into another phase	221	4.4	247	13.8
Discharge/case closure	101	2.0	148	8.2
Died	4,644	93.4	1,400	78.0
Not stated/inadequately described	5	0.1	1	0.1
Total	4,971	100.0	1,796	100.0

Figure 24 Terminal phase progression – inpatient setting





Figure 25 Terminal phase progression – community setting





The Palliative Care Problem Severity Score (PCPSS) is a clinician rated screening tool to assess the overall severity of problems within four key palliative care domains (pain, other symptoms, psychological/spiritual and family/carer). The ratings are: 0 - absent, 1 - mild, 2 - moderate and 3 - severe. The use of this tool provides an opportunity to assist in the need or urgency of intervention.

Table 30 and Table 31 show the percentage scores for the inpatient and community settings respectively.

Table 30 Profile of PCPSS at beginning of phase by phase type – inpatient setting (percentages)

•	, , ,	. , .			<i>3</i> ,
Phase type	Problem severity	Absent	Mild	Moderate	Severe
	Pain	47.8	36.9	12.6	2.7
Ctable	Other symptoms	24.8	49.6	21.6	4.0
Stable	Psychological/spiritual	30.2	51.6	15.1	3.1
	Family/carer	38.0	41.9	15.9	4.2
	Pain	29.8	30.4	27.4	12.5
Huotoblo	Other symptoms	11.5	32.7	40.9	14.9
Unstable	Psychological/spiritual	19.8	42.8	27.7	9.7
	Family/carer	24.1	36.2	28.2	11.4
	Pain	38.0	36.3	19.6	6.2
Deterioration	Other symptoms	14.9	40.0	34.9	10.2
Deteriorating	Psychological/spiritual	23.4	46.8	23.5	6.3
	Family/carer	26.4	39.2	25.3	9.1
	Pain	48.9	30.8	14.8	5.5
Terminal	Other symptoms	34.3	31.2	23.6	10.9
reminai	Psychological/spiritual	50.8	29.8	13.7	5.7
	Family/carer	23.7	32.1	29.6	14.7



Table 31 Profile of PCPSS at beginning of phase by phase type –community setting (percentages)

Problem severity	Absent	Mild	Moderate	Severe
Pain	40.8	50.3	8.2	0.7
Other symptoms	15.1	63.9	19.6	1.4
Psychological/spiritual	30.4	57.4	11.1	1.1
Family/carer	31.3	51.3	15.5	1.8
Pain	19.5	29.8	32.4	18.4
Other symptoms	5.2	26.2	49.0	19.6
Psychological/spiritual	13.3	43.7	34.3	8.6
Family/carer	14.5	34.9	38.3	12.2
Pain	28.9	48.8	19.5	2.8
Other symptoms	6.7	47.1	40.4	5.8
Psychological/spiritual	18.1	56.3	22.7	2.9
Family/carer	20.3	44.5	30.1	5.1
Pain	36.8	41.5	16.7	5.0
Other symptoms	20.3	38.8	30.7	10.2
Psychological/spiritual	40.8	39.7	15.3	4.2
Family/carer	11.5	38.4	36.5	13.6
	Pain Other symptoms Psychological/spiritual Family/carer Pain Other symptoms Psychological/spiritual	Pain 40.8 Other symptoms 15.1 Psychological/spiritual 30.4 Family/carer 31.3 Pain 19.5 Other symptoms 5.2 Psychological/spiritual 13.3 Family/carer 14.5 Pain 28.9 Other symptoms 6.7 Psychological/spiritual 18.1 Family/carer 20.3 Pain 36.8 Other symptoms 20.3 Psychological/spiritual 40.8	Pain 40.8 50.3 Other symptoms 15.1 63.9 Psychological/spiritual 30.4 57.4 Family/carer 31.3 51.3 Pain 19.5 29.8 Other symptoms 5.2 26.2 Psychological/spiritual 13.3 43.7 Family/carer 14.5 34.9 Pain 28.9 48.8 Other symptoms 6.7 47.1 Psychological/spiritual 18.1 56.3 Family/carer 20.3 44.5 Pain 36.8 41.5 Other symptoms 20.3 38.8 Psychological/spiritual 40.8 39.7	Pain 40.8 50.3 8.2 Other symptoms 15.1 63.9 19.6 Psychological/spiritual 30.4 57.4 11.1 Family/carer 31.3 51.3 15.5 Pain 19.5 29.8 32.4 Other symptoms 5.2 26.2 49.0 Psychological/spiritual 13.3 43.7 34.3 Family/carer 14.5 34.9 38.3 Pain 28.9 48.8 19.5 Other symptoms 6.7 47.1 40.4 Psychological/spiritual 18.1 56.3 22.7 Family/carer 20.3 44.5 30.1 Pain 36.8 41.5 16.7 Other symptoms 20.3 38.8 30.7 Psychological/spiritual 40.8 39.7 15.3

The Symptom Assessment Scale (SAS) is a patient rated assessment tool and reports a level of distress using a numerical rating scale from 0 - no problems to 10 - worst possible problems. The SAS reports on seven symptoms, these being difficulty sleeping, appetite problems, nausea, bowel problems, breathing problems, fatigue and pain. It provides a clinical picture of these seven symptoms from the patient's perspective. The SAS scores are grouped in Table 32 and Table 33 on the following pages using the same categories as the PCPSS i.e. absent (0), mild (1-3), moderate (4-7) and severe (8-10).



Table 32 Profile of SAS scores at beginning of phase by phase type – inpatient setting (percentages)

Phase type	Symptom distress	0 (Absent)	1-3 (Mild)	4-7 (Moderate)	8-10 (Severe)
	Difficulty sleeping	66.1	19.1	12.8	2.1
	Appetite problems	51.9	24.8	19.3	4.0
	Nausea	78.4	13.8	6.4	1.4
Stable	Bowel problems	60.8	22.7	13.3	3.1
	Breathing problems	64.5	18.3	13.7	3.5
	Fatigue	27.8	23.9	39.3	9.0
	Pain	45.6	32.6	19.1	2.6
	Difficulty sleeping	56.5	18.7	19.6	5.2
	Appetite problems	39.2	22.5	29.2	9.1
	Nausea	65.6	16.0	13.7	4.7
Unstable	Bowel problems	51.3	22.2	19.9	6.6
	Breathing problems	53.5	17.7	20.0	8.8
	Fatigue	20.2	15.6	45.9	18.3
	Pain	30.4	25.5	33.0	11.1
	Difficulty sleeping	66.9	16.1	14.2	2.8
	Appetite problems	49.1	20.6	22.7	7.6
	Nausea	74.8	13.3	9.7	2.1
Deteriorating	Bowel problems	58.6	21.5	16.1	3.8
	Breathing problems	56.4	17.6	18.8	7.2
	Fatigue	25.1	13.9	41.2	19.8
	Pain	38.5	29.6	25.9	5.9
	Difficulty sleeping	89.6	5.1	4.1	1.2
	Appetite problems	85.8	3.9	5.5	4.7
	Nausea	92.2	3.9	2.9	0.9
Terminal	Bowel problems	82.7	8.9	6.5	1.9
	Breathing problems	65.4	12.9	14.0	7.7
	Fatigue	69.6	4.2	11.6	14.5
	Pain	57.0	22.6	16.5	3.9



Table 33 Profile of SAS scores at beginning of phase by phase type –community setting (percentages)

ruible de l'rejlie (, c. 10 0001 00 at a 0 g	9 -)			9 (100:00::00:900)
Phase type	Symptom distress	0 (Absent)	1-3 (Mild)	4-7 (Moderate)	8-10 (Severe)
	Difficulty sleeping	62.5	26.3	10.1	1.1
	Appetite problems	45.7	34.3	17.9	2.1
	Nausea	79.8	16.0	3.8	0.4
Stable	Bowel problems	67.0	24.8	7.2	1.0
	Breathing problems	55.1	29.8	13.1	2.0
	Fatigue	12.2	34.1	46.6	7.1
	Pain	43.6	43.1	12.1	1.2
	Difficulty sleeping	43.6	27.0	23.9	5.5
	Appetite problems	30.8	25.7	32.9	10.6
	Nausea	58.8	19.7	14.5	7.0
Unstable	Bowel problems	53.2	25.5	16.0	5.3
	Breathing problems	47.2	25.2	20.5	7.1
	Fatigue	7.8	16.4	52.3	23.5
	Pain	19.9	25.6	36.8	17.8
	Difficulty sleeping	56.3	27.2	14.6	2.0
	Appetite problems	37.5	30.0	26.6	5.9
	Nausea	71.6	19.9	7.1	1.4
Deteriorating	Bowel problems	59.7	27.6	10.9	1.8
	Breathing problems	47.9	30.0	18.7	3.4
	Fatigue	8.9	20.5	55.3	15.2
	Pain	33.0	41.0	22.8	3.2
	Difficulty sleeping	74.1	13.4	9.8	2.7
	Appetite problems	73.8	7.1	7.2	12.0
	Nausea	84.9	10.2	3.9	1.0
Terminal	Bowel problems	74.1	16.9	7.9	1.0
	Breathing problems	54.3	22.5	16.9	6.4
	Fatigue	54.3	4.5	15.0	26.2
	Pain	41.7	34.1	20.2	4.1



The Australia-modified Karnofsky Performance Status (AKPS) is a measure of the patient's overall performance status or ability to perform their activities of daily living. It is a single score between 0 and 100 assigned by a clinician based on observations of a patient's ability to perform common tasks relating to activity, work and self-care. Table 34 shows the data for the AKPS at phase start.

Table 34 Australia-modified Karnofsky Performance Status (AKPS) at phase start by setting

AKPS assessment	Inpa	tient	Community	
ARPS assessment	N	%	N	%
10 - Comatose or barely rousable	2,623	10.1	727	3.2
20 - Totally bedfast and requiring extensive nursing care	5,848	22.5	2,079	9.2
30 - Almost completely bedfast	3,515	13.5	1,563	6.9
40 - In bed more than 50% of the time	4,637	17.8	2,576	11.4
50 - Requires considerable assistance	4,594	17.7	5,121	22.7
60 - Requires occasional assistance	2,571	9.9	5,782	25.6
70 - Cares for self	622	2.4	3,394	15.0
80 - Normal activity with effort	182	0.7	805	3.6
90 - Able to carry on normal activity; minor signs or symptoms	59	0.2	171	0.8
100 - Normal; no complaints; no evidence of disease	3	0.0	7	0.0
Not stated/inadequately described	1,359	5.2	342	1.5
Total	26,013	100.0	22,567	100.0

The Resource Utilisation Groups – Activities of Daily Living (RUG-ADL) consists of four items (bed mobility, toileting, transfers and eating) and assesses the level of functional dependence. The RUG-ADL are assessed daily (or at each visit) and are reported on admission, when the phase changes and at discharge. Figure 26 and Figure 27 on the following two pages summarise the total RUG-ADL at the beginning of each phase for inpatients and community patients. The total score on the RUG-ADL ranges from a minimum of 4 (lowest level of functional dependency) to a maximum of 18 (highest level of functional dependency).

AKPS & RUG-ADL can be used together to provide a profile of both patient dependency, equipment requirements, need for allied health referrals and carer burden/respite requirements.



Figure 26 Total RUG-ADL at beginning of phase by phase type – inpatient setting







Figure 27 Total RUG-ADL at beginning of phase by phase type – community setting





Appendix A Summary of data included in this report

A1 Data summary

During the reporting period, data were provided for a total of 16,642 patients who between them had 21,518 episodes of care and 49,643 palliative care phases. These total numbers are determined by a data scoping method. This method looks at the phase level data first and includes all phases that ended within the current reporting period. The associated episodes and patients are then determined (Appendix B contains a more detailed explanation of this process). Table 35 shows the number of patients, episodes and phases included in this report.

A consequence of the data scoping method is that it is likely that not all phases related to a particular episode are included in this report. Hence, the average number of phases per episode calculation shown in Table 35 may be an underestimate (due to episodes that cross-over 2 or more reporting periods) as it only includes phases that ended within the current reporting period.

Table 35 Number and percentage of patients, episodes and phases by setting

	Inpatient	Community	Total
Number of patients*	9,509	8,234	16,833
Number of episodes	11,286	10,232	21,518
Number of phases	26,887	22,756	49,643
Percentage of patients*	55.5	48.9	100
Percentage of episodes	52.4	47.6	100
Percentage of phases	54.2	45.8	100
Average number of phases per episode**	2.3	2.1	2.2

^{*} Patients seen in both settings are only counted once in the total column and hence numbers/percentages may not add to the total.

^{**} Average number of phases per episode is only calculated for closed episodes that started and ended within the reporting period and excludes bereavement phases.



Table 36 shows the number of completed episodes and phases by setting in the current reporting period. This table identifies any change in patient numbers during the reporting period.

Table 36 Number of completed episodes and phases by month and setting

		Jan	Feb	Mar	Apr	May	Jun
Innations	No. of completed episodes	1,736	1,825	1,992	1,896	1,937	1,771
Inpatient	No. of completed phases	4,576	4,514	4,695	4,616	4,727	3,759
Community	No. of completed episodes	1,640	1,441	1,561	1,457	1,513	1,508
Community	No. of completed phases	4,101	3,523	3,710	3,677	4,011	3,734



A2 Data item completion

As shown in Table 37, Table 38 and Table 39 below, the rate of data completion is very high. In reviewing these tables, it is important to note that in some cases some data items are not required to be completed. For example, place of death is only required for community patients who have died. Hence the complete column in the following tables only refers to the percentage of complete records where the data item was relevant.

PCOC strongly encourages services to complete and submit the whole data set on every patient as non-completion may result in services being excluded from relevant benchmarking activities or erroneous conclusions being drawn. Low completion of data items may also distort percentages and graphs in some sections.

Table 37 Item completion (per cent complete) - patient level

Data item	Total
Date of birth	100.0
Sex	100.0
Indigenous status	98.0
Country of birth	98.8
Preferred language	99.9
Primary diagnosis	99.6

Note: This table is not split by setting to be consistent with the patient level analysis throughout this report.

Table 38 Item completion by setting (per cent complete) - episode level

Data item	Inpatient	Community	Total
Date of first contact	100.0	99.9	99.9
Referral date	100.0	99.9	100.0
Referral source	99.4	98.4	98.9
Date ready for care	96.3	99.9	98.0
Mode of episode start	99.9	99.4	99.7
Accommodation at episode start	99.7	97.0	98.2
Episode end date	99.6	92.8	96.4
Mode of episode end	97.0	99.9	98.4
Accommodation at episode end	98.3	93.1	96.8
Place of death	na	97.7	97.7



Table 39 Item completion by setting (per cent complete) - phase level

	Sub-Category	At phase start			At discharge			
Data item	ata item (where applicable)		Community	Total	Inpatient	Community	Total	
	Bed mobility	99.6	97.9	98.8	83.8	60.9	71.0	
RUG-ADL	Toileting	99.6	97.5	98.6	83.8	60.8	71.0	
	Transfers	99.6	96.8	98.3	83.8	60.8	71.0	
	Eating	99.4	95.2	97.4	83.8	60.3	70.7	
PCPSS	Pain	98.0	98.1	98.0	82.8	60.4	70.3	
	Other symptom	97.8	97.4	97.6	82.7	59.9	70.0	
	Psychological/spiritual	99.5	97.8	98.7	83.5	60.2	70.6	
	Family/carer	96.7	96.8	96.7	77.8	59.7	67.7	
	Difficulty sleeping	93.3	94.1	93.7	77.4	58.4	66.8	
	Appetite problems	93.7	95.0	94.3	77.5	59.9	67.7	
SAS	Nausea	93.7	96.9	95.2	77.5	60.4	68.0	
SAS	Bowel problems	93.5	95.3	94.4	77.5	59.5	67.5	
	Breathing problems	93.7	96.5	95.0	77.5	60.4	68.0	
	Fatigue	93.6	96.2	94.8	77.6	60.4	68.0	
	Pain	93.7	97.7	95.6	77.6	61.1	68.4	
AKPS	-	94.8	98.5	96.5	81.2	60.6	69.8	


Data item	Inpatient	Community	Total
Phase End Reason	99.9	99.9	99.9



Appendix B Data scoping method

The method used to determine which data is included in a PCOC report looks at the phase level records first. All phase records that <u>end</u> within the 6 month reporting period are deemed to be "in scope" and would be included in the report. The episode and patient records associated with these phases are also deemed to be "in scope" and hence would also be included in the report. Figure 28 below displays four examples to help visualize this process.





In <u>Example 1</u>, the patient (represented by the green line) has one episode (represented by the blue line). This episode has six phases (represented by the purple line segments). All six phases would be included in the report as they all end within the reporting period. Hence, the episode and patient would also be in the report.

In <u>Example 2</u>, the patient has two episodes - the first having six phases and the second having seven phases. Looking at the phases associated with the first episode, the last four will be included in the report (as they end within the reporting period). The first two phases would have been included in the previous report. For the phases relating to the second episode, only the first three end within the reporting period, so only these would be included in the report. The following four phases would be included in the next report. Both of the episode records and the patient record would also be included in the report.

In <u>Example 3</u>, the patient has one episode and five phases. Only the last three phases will be included in the report as they are the only ones ending within the reporting period (the first two phases would have been included in the previous report). The episode and patient records would be included in the report.

In <u>Example 4</u>, the patient again has one episode and five phases. This time, only the first three phases will be included in the report (the last two phases will be included in the next report). Again, the episode and patient records would be included in the report.



Appendix C X-CAS technical notes

The procedure for calculating X-CAS is as follows:

- **Step 1.** Using the baseline data, calculate the average change in symptom for <u>all patients</u> in the same phase, having the same symptom start score. This is called the **expected** change.
- **Step 2.** For each individual phase, calculate the change in symptom score (start score minus end score).
- **Step 3.** For each individual phase, calculate the difference between their <u>change in symptom score</u> (calculated in step 2) and the relevant expected change (calculated in step 1).
- **Step 4.** Average all of the values calculated in step 3 to produce the service's Symptom Casemix-Adjusted Score (e.g. PCAS).

Example:

Phase	PCPSS Pain	PCPSS Pain	Step 1: Expected PCPSS Pain change	Step2: PCPSS Pain change	Step 3: Difference	Step 4: Average of values in step 3
	at start	at end	(from Report 6 National Database)	(start score minus end score)	(Step 2 minus Step 1)	
Stable	0	1	-0.8	-1	-0.2	
Stable	1	1	-0.9	0	0.9	<u>-0.2+0.9+0.4-0.4</u>
Unstable	3	1	1.6	2	0.4	4
Deteriorating	2	1	1.4	1	-0.4	= 0.175



Appendix D Palliative Care Phase definitions

START	END				
1. Stable					
Patient problems and symptoms are adequately controlled by established plan of care and Further interventions to maintain symptom control and quality of life have been planned and Family/carer situation is relatively stable and no new issues are apparent.	The needs of the patient and / or family/carer increase, requiring changes to the existing plan of care.				
2. Unstable					
 An urgent change in the plan of care or emergency treatment is required because Patient experiences a new problem that was not anticipated in the existing plan of care, and/or Patient experiences a rapid increase in the severity of a current problem; and/or Family/ carers circumstances change suddenly impacting on patient care. 	 The new plan of care is in place, it has been reviewed and no further changes to the care plan are required. This does not necessarily mean that the symptom/crisis has fully resolved but there is a clear diagnosis and plan of care (i.e. patient is stable or deteriorating) and/or Death is likely within days (i.e. patient is now terminal). 				
3. Deteriorating					
 The care plan is addressing anticipated needs but requires periodic review because Patients overall functional status is declining and Patient experiences a gradual worsening of existing problem and/or Patient experiences a new but anticipated problem and/or Family/carers experience gradual worsening distress that impacts on the patient care. 	 Patient condition plateaus (i.e. patient is now stable) or An urgent change in the care plan or emergency treatment and/or Family/ carers experience a sudden change in their situation that impacts on patient care, and urgent intervention is required (i.e. patient is now unstable) or Death is likely within days (i.e. patient is now terminal). 				
4. Terminal					
Death is likely within days.	 Patient dies or Patient condition changes and death is no longer likely within days (i.e. patient is now stable or deteriorating). 				
5. Bereavement – post death support					
 The patient has died Bereavement support provided to family/carers is documented in the deceased patient's clinical record. 	 Case closure Note: If counselling is provided to a family member or carer, they become a client in their own right. 				



Acknowledgements

Disclaimer

Copyright

Suggested Citation

Contributions PCOC wishes to acknowledge the valuable contribution made by the many staff from palliative care services who have spent considerable time collecting, collating and correcting the data and without whose effort this report would not be possible.

PCOC has made every effort to ensure that the data used in this report are accurate. Data submitted to PCOC are checked for anomalies and services are asked to re-submit data prior to the production of the PCOC report. We would advise readers to use their professional judgement in considering all information contained in this report.

This work is copyright. It may be produced in whole or in part for study or training purposes subject to the inclusion of an acknowledgement of the source. It is not for commercial usage or sale. Reproduction for purposes other than those above requires the written permission of PCOC.

Holloway A, Allingham S, Clapham S, Quinsey K, and Foskett L (2014) *National Report on Patient Outcomes in Palliative Care in Australia, Report 17 (January – June 2014)*. Palliative Care Outcomes Collaboration, Australian Health Services Research Institute, University of Wollongong